# Pharmacokinetics of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048

> **NCT02419456** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 19 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** MK-2048A IVR (Low Dose)
- **DRUG:** MK-2048A IVR (Original Dose)

## Key facts

- **NCT ID:** NCT02419456
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2021-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02419456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02419456, "Pharmacokinetics of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02419456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*